JOHN C. VAUGHAN, M.D.
Medical Practice at Genesee Ave, La Jolla, CA

RE33897, Apr 21, 1992

Mar 29, 1989

7/330320

John H. Vaughan - La Jolla CA
Dennis A. Carson - Del Mar CA
Gary Rhodes - Leucadia CA
Richard A. Houghton - Solana Beach CA

Scripps Clinic and Research Foundation - La Jolla CA

C07K 708

530326

Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic, random copolymer polypeptide having about 6 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the five amino acid residue sequence -Gly-R. sup. 1 -Gly-R. sup. 2 -Gly-, wherein R. sup. 1 and R. sup. 2 are the same or different amino acid residues selected from the group consisting of Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr, with the provision that R. sup. 1 and R. sup. 2 are not both Gly. The polypeptide contains at least 25 mole percent Gly residues, and when linked to a carrier and introduced in an effective amount into a mammalian host is capable of inducing production of antibodies that immunoreact with EBNA.

5116725, May 26, 1992

Nov 4, 1987

7/117241

John H. Vaughan - La Jolla CA
Dennis A. Carson - Del Mar CA
Gary Rhodes - Leucadia CA
Richard Houghten - Solana Beach CA
Richard S. Smith - Del Mar CA
John E. Geltosky - Doylestown PA

Scripps Clinic and Research Foundation - La Jolla CA

C12Q 170, C12Q 128, G01N 33543, C07K 708

435 5

Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences (i) --Gly--R. sup. 1 --Gly--R. sup. 2 --Gly-- wherein R. sup. 1 and R. sup. 2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R. sup. 1 and R. sup. 2 are not both Gly; and (ii) --Gly--Ala--Gly--Gly--Ala--Gly--. The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma. In an assay for determining the state of Epstein-Barr virus infection, the synthetic polypeptide is fixed to first and second solid phases supports which can be provided by a double-welled spoon having two adjacent solid phases.

5122448, Jun 16, 1992

Jan 11, 1990

7/463505

John H. Vaughan - La Jolla CA
Dennis A. Carson - Del Mar CA
Gary Rhodes - Leucadia CA
Richard Houghten - Solana Beach CA

Scripps Clinic and Research Foundation - La Jolla CA

C12Q 170, G01N 3353, G01N 33535, G01N 33545

435 5

Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences --Gly--R. sup. 1 --Gly--R. sup. 2 --Gly-- (i) wherein R. sup. 1 and R. sup. 2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R. sup. 1 and R. sup. 2 are not both Gly; and --Gly--Ala--Gly--Gly--Ala--Gly--. (ii) The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma. Assaying for anti-Epstein-Barr virus nuclear antigen antibodies is carried out by mixing a body sample with the synthetic polypeptide, allowing antibodies in the sample to immunoreact with the polypeptide to form an immunoreactant and determin This invention was made with the support of the United States Government, and the United States Government has certain rights in the invention.

4654419, Mar 31, 1987

Aug 8, 1984

6/638726

John H. Vaughan - La Jolla CA
Dennis A. Carson - Del Mar CA
Gary Rhodes - Leucadia CA
Richard Houghten - Solana Beach CA

Scripps Clinic and Research Foundation - La Jolla CA

C07K 708

530326

Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic, random copolymer polypeptide having about 6 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the five amino acid residue sequence -Gly-R. sup. 1 -Gly-R. sup. 2 -Gly-, wherein R. sup. 1 and R. sup. 2 are the same or different amino acid residues selected from the group consisting of Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr, with the provision that R. sup. 1 and R. sup. 2 are not both Gly. The polypeptide contains at least 25 mole percent Gly residues, and when linked to a carrier and introduced in an effective amount into a mammalian host is capable of inducing production of antibodies that immunoreact with EBNA.